Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 15/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 13/20 | 0.45 |
| ▸ | PI4KA | P42356 | 1/20 | 0.41 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.41 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18026301 | 1.00 | PRMT5 (0.45) | PRMT5WDR77PI4KAPI4K2BPI4K2A | |
| SCHEMBL18026198 | 0.84 | PRMT5 (0.47) | PRMT5WDR77PI4KAPI4K2BPI4K2A | |
| SCHEMBL13170765 | 0.84 | PRMT5 (0.47) | PRMT5WDR77PI4KAPI4K2BPI4K2A | |
| SCHEMBL18009818 | 0.83 | PI4KA (0.58) | PRMT5WDR77PI4KAPI4K2BPI4K2A | |
| SCHEMBL18009834 | 0.83 | PI4KA (0.58) | PRMT5WDR77PI4KAPI4K2BPI4K2A | |
| SCHEMBL18039037 | 0.82 | PRMT5 (0.41) | PRMT5WDR77PI4KAPI4K2BPI4K2A | |
| SCHEMBL18026300 | 0.82 | PRMT5 (0.53) | PRMT5WDR77 | |
| SCHEMBL18009864 | 0.82 | PRMT5 (0.53) | PRMT5WDR77 | |
| SCHEMBL21413885 | 0.82 | PRMT5 (0.53) | PRMT5WDR77 | |
| SCHEMBL18026119 | 0.82 | PRMT5 (0.53) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3262057-B1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2020-04-15 | — | — | EP | disclosed |
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-10-01 | — | — | US | disclosed |
| EP-3262057-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Inc (US) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016135582-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | TYMP, NME1, DPYD | PRMT5 1543/4885WDR77 2428/4885PI4KA 769/4885 |
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | TYMP, NME1, PNP | PRMT5 1552/4885WDR77 2124/4885PI4KA 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.